{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:08:40Z","timestamp":1788390520154,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Persons living with human immunodeficiency virus are an underserved population for evidence-based cancer treatment. Paclitaxel and carboplatin (PCb) is an active regimen against a variety of solid tumors, including several seen in excess in patients with HIV infection. We performed a pilot trial to evaluate the safety of full-dose PCb in people living with human immunodeficiency virus and cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients, stratified by concurrent antiretroviral therapy (ART) that included CYP3A4 inhibitors or not, received paclitaxel (175\u00a0mg\/m2) in combination with carboplatin (target AUC 6) intravenously every 3 weeks for up to 6 cycles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixteen evaluable patients received 64 cycles of PCb, including 6 patients treated with CYP3A4 inhibiting ART (ritonavir). The adverse event profile was consistent with the known toxicity profile of PCb, with no differences between the 2 strata. There were 4 partial responses (25%, 95% CI: 7%-52%), and overall, CD4+ lymphocyte count was similar after completion of therapy (median: 310\/\u03bcL) compared with baseline values (median: 389\/\u03bcL). Pharmacokinetic studies in 6 patients revealed no significant differences in Cmax or AUCinf for paclitaxel between the 2 cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Full doses of PCb chemotherapy are tolerable when given concurrently with ART in people living with human immunodeficiency virus with cancer, including patients receiving CYP3A4 inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                  <jats:p>NCT01249443.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac004","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T12:11:50Z","timestamp":1643285510000},"page":"623-e624","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study"],"prefix":"10.1093","volume":"27","author":[{"suffix":"Jr","given":"Missak","family":"Haigentz","sequence":"first","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey , New Brunswick, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page","family":"Moore","sequence":"additional","affiliation":[{"name":"CorEvitas , Waltham, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Bimali","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences , Little Rock, AK , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cooley","sequence":"additional","affiliation":[{"name":"Boston Medical Center , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sparano","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rudek","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Ratner","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine , St. Louis, MO , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Henry","sequence":"additional","affiliation":[{"name":"Pennsylvania Hospital , Philadelphia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ramos","sequence":"additional","affiliation":[{"name":"University of Miami School of Medicine , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Deeken","sequence":"additional","affiliation":[{"name":"Inova Schar Cancer Institute , Fairfax, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"John H. Stroger, Jr. Hospital of Cook County , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5752-2916","authenticated-orcid":false,"given":"Elizabeth","family":"Chiao","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Baylor College of Medicine , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"issue":"4","key":"2022080910381965400_CIT0001","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00280-010-1509-4","article-title":"Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi\u2019s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial.","volume":"68","author":"Cianfrocca","year":"2011","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1","key":"2022080910381965400_CIT0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","article-title":"Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer.","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J Clin Oncol."},{"issue":"14","key":"2022080910381965400_CIT0003","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/rcm.2577","article-title":"Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography\/tandem mass spectrometry.","volume":"20","author":"Gardner","year":"2006","journal-title":"Rapid Commun Mass Spectrom."},{"issue":"2","key":"2022080910381965400_CIT0004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/0003-4819-150-2-200901200-00300","article-title":"Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association.","volume":"150","author":"Qaseem","year":"2009","journal-title":"Ann Intern Med."},{"issue":"3","key":"2022080910381965400_CIT0005","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.2010.752","article-title":"Time for oncologists to opt in for routine opt-out HIV testing?","volume":"304","author":"Chiao","year":"2010","journal-title":"JAMA."},{"issue":"13","key":"2022080910381965400_CIT0006","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med."},{"key":"2022080910381965400_CIT0007","author":"Organization WH.","year":"2015"},{"issue":"2","key":"2022080910381965400_CIT0008","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/QAI.0000000000000960","article-title":"Population-based estimates of life expectancy after HIV diagnosis: United States 2008-2011.","volume":"72","author":"Siddiqi","year":"2016","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"10","key":"2022080910381965400_CIT0009","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-148-10-200805200-00005","article-title":"Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.","volume":"148","author":"Patel","year":"2008","journal-title":"Ann Intern Med."},{"issue":"9","key":"2022080910381965400_CIT0010","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States.","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst."},{"issue":"6","key":"2022080910381965400_CIT0011","doi-asserted-by":"crossref","first-page":"e0129550","DOI":"10.1371\/journal.pone.0129550","article-title":"Cancer-related causes of death among HIV-infected patients in France in 2010: evolution since 2000.","volume":"10","author":"Vandenhende","year":"2015","journal-title":"PLoS One."},{"issue":"5","key":"2022080910381965400_CIT0012","doi-asserted-by":"crossref","first-page":"335","DOI":"10.7326\/M14-0954","article-title":"Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys.","volume":"162","author":"Mdodo","year":"2015","journal-title":"Ann Intern Med."},{"issue":"2","key":"2022080910381965400_CIT0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1378\/chest.12-1699","article-title":"Epidemic of lung cancer in patients with HIV infection.","volume":"143","author":"Winstone","year":"2013","journal-title":"Chest."},{"issue":"1","key":"2022080910381965400_CIT0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cllc.2011.05.005","article-title":"Lung cancer in HIV infection.","volume":"13","author":"Mani","year":"2012","journal-title":"Clin Lung Cancer."},{"issue":"2","key":"2022080910381965400_CIT0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12105-010-0171-9","article-title":"Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations.","volume":"4","author":"McLemore","year":"2010","journal-title":"Head Neck Pathol."},{"issue":"6","key":"2022080910381965400_CIT0016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000215719","article-title":"Clinical presentation and outcome of colorectal cancer in HIV-positive patients: a clinical case-control study.","volume":"32","author":"Berretta","year":"2009","journal-title":"Onkologie."},{"issue":"1","key":"2022080910381965400_CIT0017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/COH.0000000000000332","article-title":"Malignancies in women with HIV infection.","volume":"12","author":"Oliver","year":"2017","journal-title":"Curr Opin HIV AIDS."},{"issue":"11","key":"2022080910381965400_CIT0018","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1055-9965.EPI-10-0741","article-title":"Reduced risk of prostate cancer in U.S. men with AIDS.","volume":"19","author":"Shiels","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"5","key":"2022080910381965400_CIT0019","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/QAI.0000000000000202","article-title":"Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men.","volume":"66","author":"Marcus","year":"2014","journal-title":"J Acquir Immune Defic Syndr."},{"issue":"6","key":"2022080910381965400_CIT0020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/nrurol.2010.61","article-title":"Management of prostate cancer in HIV-positive patients.","volume":"7","author":"Wosnitzer","year":"2010","journal-title":"Nat Rev Urol."},{"issue":"9","key":"2022080910381965400_CIT0021","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS.","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol."},{"issue":"8","key":"2022080910381965400_CIT0022","doi-asserted-by":"crossref","first-page":"986","DOI":"10.6004\/jnccn.2018.0066","article-title":"Cancer in people living with HIV, version 1.2018, NCCN clinical practice guidelines in oncology.","volume":"16","author":"Reid","year":"2018","journal-title":"J Natl Compr Canc Netw."},{"issue":"12","key":"2022080910381965400_CIT0023","first-page":"1904","article-title":"Disparities and determinants of cancer treatment in elderly Americans living with human immunodeficiency virus\/AIDS.","volume":"67","author":"Rositch","year":"2018","journal-title":"Clin Infect Dis."},{"issue":"12","key":"2022080910381965400_CIT0024","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/jphp.12820","article-title":"Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat.","volume":"69","author":"Hossain","year":"2017","journal-title":"J Pharm Pharmacol."},{"issue":"16","key":"2022080910381965400_CIT0025","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1002\/cncr.25362","article-title":"Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.","volume":"116","author":"Cianfrocca","year":"2010","journal-title":"Cancer."},{"issue":"1","key":"2022080910381965400_CIT0026","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.coc.0000045921.91037.C8","article-title":"Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma.","volume":"27","author":"Bundow","year":"2004","journal-title":"Am J Clin Oncol."},{"issue":"2","key":"2022080910381965400_CIT0027","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002030-199902040-00019","article-title":"Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi\u2019s sarcoma.","volume":"13","author":"Schwartz","year":"1999","journal-title":"AIDS."},{"key":"2022080910381965400_CIT0028","volume-title":"Guidelines for the","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents."},{"issue":"22","key":"2022080910381965400_CIT0029","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct.","volume":"38","author":"Rao","year":"2020","journal-title":"J Clin Oncol."},{"issue":"24","key":"2022080910381965400_CIT0030","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med."},{"issue":"21","key":"2022080910381965400_CIT0031","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med."},{"issue":"24","key":"2022080910381965400_CIT0032","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/623\/45293583\/oyac004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/623\/45293583\/oyac004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:39:10Z","timestamp":1660041550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/8\/623\/6569249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4,16]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac004","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,4,16]]}}}